Look for Post-MI Patients Who May Benefit From an Aldosterone Antagonist
December 2017
You'll hear more buzz about starting an aldosterone antagonist (spironolactone, eplerenone) in eligible post-MI patients.
This isn't new information. We know adding an aldosterone antagonist to post-MI patients with "systolic" heart failure...or HFrEF...reduces mortality. But less than 20% of patients are started on one.
Help close the gap.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote